Table 1 Top mutated genes with predicted HLA DRB1 binding neo-peptides in lung adenocarcinoma patients in this study
Gene | No. of strong-binding neo-antigens | No. of weak-binding neo-antigens | Other mutant peptides | Total mutated peptides | Frequency of neo-antigens in 147 samples |
|---|---|---|---|---|---|
KRAS | 0 | 48 | 3 | 51 | 32.65% |
TTN | 1 | 44 | 101 | 146 | 22.45% |
RYR2 | 0 | 36 | 43 | 79 | 20.41% |
MUC16 | 2 | 35 | 58 | 95 | 20.41% |
TP53 | 1 | 25 | 37 | 63 | 17.01% |
USH2A | 1 | 24 | 25 | 50 | 13.61% |
ZFHX4 | 1 | 21 | 42 | 64 | 14.29% |
KEAP1 | 1 | 19 | 10 | 30 | 13.61% |
STK11 | 1 | 17 | 17 | 35 | 11.56% |
FAT3 | 0 | 15 | 14 | 29 | 7.48% |
NAV3 | 2 | 14 | 16 | 32 | 10.20% |
EGFR | 0 | 14 | 10 | 24 | 8.16% |
SPTA1 | 0 | 13 | 31 | 44 | 8.84% |
ANK2 | 0 | 13 | 14 | 27 | 7.48% |
ADAMTS12 | 0 | 13 | 22 | 35 | 6.12% |
PXDNL | 0 | 12 | 11 | 23 | 8.16% |
DMD | 0 | 12 | 14 | 26 | 8.16% |
ASPM | 0 | 12 | 6 | 18 | 8.16% |
LPHN3 | 1 | 11 | 10 | 22 | 8.16% |
DNAH9 | 0 | 11 | 15 | 26 | 6.12% |